2026-11-13. The following slide deck was published by Novanta Inc.
Novanta reported Q3 2026 sales of US$305.01 million with GAAP net income of US$2.02 million, while adjusted metrics and revenue topped analyst expectations, and management reiterated 2026 revenue guidance alongside Q4 forecasts. The recent period put Riverpoint Medical at the center of Novanta's story, with management highlighting the large acquisition's early contribution to consumables and the broader product pipeline. We will look at how Novanta's investment narrative is influenced by Q3...
Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) will be reporting results this Monday afternoon. Here’s what to expect.
For questions about this article or underlying research, email help@trefis.com.
ACCESS Newswire Press Release.
Novanta (NASDAQ:NOVT) has outperformed the market over the past 15 years by 7.15% on an annualized basis producing an average annual return of 20.4%. Currently, Novanta has a market capitalization of $4.86 billion.
Novanta (NASDAQ:NOVT) has outperformed the market over the past 15 years by 8.22% on an annualized basis producing an average annual return of 21.59%. Currently, Novanta has a market capitalization of $5.13 billion.
Recent commentary on Novanta (NOVT) has focused on its revenue growth profile and projected demand pickup, with solid gross margins drawing new attention to how the stock’s recent returns compare with those fundamentals. Short term trading pressure has been clear, with the share price down 9.2% over the past week and 14.3% over 90 days. Yet Novanta’s year to date share price return of 19.8% and 1 year total shareholder return of 16.1% point to momentum that has cooled rather than...
In recent commentary, Novanta (NASDAQ:NOVT) has been highlighted for its multi-year annual revenue growth of 10.7% and a gross margin of 44.4%, reflecting perceived market share gains and strong product positioning. This attention centers on Novanta’s combination of demand acceleration expectations and high-margin products, which analysts view as evidence of superior competitive capabilities. Next, we will examine how this focus on Novanta’s revenue momentum and margins may influence the...
On August 5, Novanta Inc. (NASDAQ:NOVT) reported second quarter results showing something rarer than strong revenue growth: profit growth that beat it by a wide margin. Revenue rose 10.3% year over year to $265.8 million, but net income nearly tripled and cash from operations quadrupled. That kind of gap between the top and bottom line […]
BOSTON, August 28, 2026--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY.
Detailed price information for Novanta Inc (NOVT-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.